The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2020RT-QuIC Testing of Misfolded Alpha-synuclein in S4 Study Samples
Study Rationale:
The protein alpha-synuclein is vital to normal brain function. In Parkinson's disease, alpha-synuclein misfolds, forming aggregates, or clumps, that impair the ability of brain cells... -
Therapeutic Pipeline Program, 2020Anle138b Clinical Phase 1 Studies: Food Effect, Safety and Tolerability as well as Pharmacokinetics in Parkinson´s Disease Patients
Study Rationale:
Clumps of the protein alpha-synuclein, called Lewy bodies, are a hallmark of Parkinson’s disease and a promising target for therapeutic development. Anle138b is a drug-like compound... -
Research Grant, 2020UCLA-California PD Registry-EHR (UCE-PD) Demonstration Project
Study Rationale:
We want to improve the quality of data being collected by the California Parkinson’s Disease Registry (CPDR). The CPDR now requires all clinicians in the state of California to report... -
Target Advancement Program, 2020The Role of Cannabinoid Receptor 2 in Inflammatory Responses Triggered by Alpha-synuclein
Study Rationale:
There is growing interest in the anti-inflammatory properties of cannabis-related compounds as a potential therapy for Parkinson’s disease (PD). Cannabis, or marijuana, acts on... -
Therapeutic Pipeline Program, 2020Phase II Trial of Bone Marrow-Derived Mesenchymal Stem Cells as a Disease-Modifying Therapy for Parkinson’s Disease
Study Rationale:
Chronic brain inflammation plays a critical role in the development and progression of Parkinson’s disease. This inflammation damages the brain, disrupts the blood-brain barrier, and... -
Improved Biomarkers and Clinical Outcome Measures, 2020Predicting Conversion to Parkinson’s Disease Based on Proteomic Biomarkers in a Large Prospective Cohort
Study Rationale:
The ultimate aim in Parkinson’s disease research is to identify individuals at risk for developing Parkinson’s prior to disease onset. To reach this goal, a set of informative markers...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.